Oral Slow-Release Ketamine for Hard-to-Treat Depression: Two Clinical Trials

Conflict of Interest Disclosures: Prof Walter reported having an institutional advisory role with HMNC, receiving personal fees from Janssen, receiving speaker compensation from Heel, receiving advisor compensation from Boehringer Ingelheim, and participating in an institutional study with Perception Neuroscience during the conduct of the study. Dr zu Eulenburg reported holding shares in and receiving consulting fees from HMNC Holding GmbH (one of the owners of the study sponsor, Ketabon GmbH) outside the submitted work. Ms Damyanova reported receiving personal fees from HMNC Holding GmbH during the study and outside the submitted work. Dr Papanastasiou reported receiving personal fees from HMNC Holding GmbH during the study and outside the submitted work. Ms Strote reported receiving personal fees from HMNC Holding GmbH during the study and outside the submitted work. Dr Gehrlach reported receiving personal fees from HMNC Holding GmbH during the study and outside the submitted work. Dr Eriksson reported receiving personal fees from and having stock options in HMNC Holding GmbH during the conduct of the study and outside the submitted work and having a pending patent application for an induction regimen for the administration of 2-(2-chlorphenyl)-2-(methylamino)cyclohexan-1-one. No other disclosures were reported.